[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@PGainz96934 Avatar @PGainz96934 Pasha Gainz

Pasha Gainz posts on X about $alt, alt, $cake, $amd the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence cryptocurrencies stocks technology brands finance

Social topic influence $alt #15, alt, $cake, $amd, weight loss, mash, money, instead of, loading, $btc

Top assets mentioned AltLayer (ALT) PancakeSwap (CAKE) Advanced Micro Devices (AMD) Bitcoin (BTC) Synthetify (SNY) Amgen, Inc. (AMGN)

Top Social Posts #

Top posts by engagements in the last XX hours

"@JamesWynnReal Very much agreed BTC sub 100k. Just posted that earlier today"
X Link @PGainz96934 2025-10-18T04:56Z XXX followers, XX engagements

"@MartinShkreli Martin bro check out $ALT. Im positive youll see the ridiculous potential and the fact its possibly one of the best asymmetrical investments in the bio space"
X Link @PGainz96934 2025-10-10T18:37Z XXX followers, 1017 engagements

"Theyve got the potential but if they actually made strategic acquisitions like acquiring a company such as $ALT they wouldnt be facing the issues they are now. Instead of blowing money on aimless or idiotic deals they should focus on transformative ones that add real long-term value and innovation to the pipeline"
X Link @PGainz96934 2025-10-12T14:57Z XXX followers, XXX engagements

"If this pullback continues heres my buy plan: $ALT: continue buying every day all day until double digits $AMD: continue loading under $XXX $BTC: slowly start accumulating below $100K $CAKE: continue weekly buys until $XX Simple. Disciplined. Long-term focused"
X Link @PGainz96934 2025-10-17T21:14Z XXX followers, XXX engagements

"$ALT Pemvidutide isnt just another GLP-1. Its rationally designed to hit the liver and metabolic system directly. This is a true dual-target therapy for serious liver disease. ✅ Liver: Class-leading MASH results with proven benefit at just XX weeks ✅ Weight loss: Continues to improve through XX weeks (MOMENTUM trial) ✅ Tolerability: Best-in-class safety profile no titration needed ✅ Pipeline: Active trials in MASH AUD and ALD Altimmune is building what could become the most complete metabolic drug on the market. Fat loss liver healing and unmatched safety in one molecule. #MASH #Obesity #GLP1"
X Link @PGainz96934 2025-10-06T14:21Z XXX followers, XXX engagements

"The heterogeneity of MASLD is exactly why $ALT is positioned to lead the MASH race. Pemvidutide isnt just another GLP-1 its dual GLP-1/glucagon design directly targets hepatic fat metabolism and drives potent weight loss with clean tolerability. ALTs data already showed broad response across patient phenotypes strong NIT & AI-driven fibrosis signals and the flexibility to hit both obesity and MASH fronts. When others struggle to show consistency across such a diverse disease spectrum. ALTs mechanism metabolic depth and precision modeling make it the most balanced play in this space"
X Link @PGainz96934 2025-10-10T14:03Z XXX followers, XX engagements

"$ALT $SNY $AMGN Big game in MASH: the FDA accepted a Letter of Intent to qualify VCTE / FibroScan (liver stiffness) as a reasonably likely surrogate endpoint in non-cirrhotic MASH trials. Thats a regulatory milestone. Now layer on top Altimmunes 48-week IMPACT readout + EoP2 timing things could get explosive"
X Link @PGainz96934 2025-10-10T18:43Z XXX followers, XXX engagements

"@TheLongInvest Nothing until they acquire something of value like $ALT"
X Link @PGainz96934 2025-10-14T16:06Z XXX followers, XXX engagements

"@0xReflection Horrible advice 🤣"
X Link @PGainz96934 2025-10-16T22:02Z XXX followers, XX engagements

"@StockMKTNewz These BPs need to look to the future and acquire $ALT"
X Link @PGainz96934 2025-10-16T22:29Z XXX followers, 1073 engagements

"Are we buying this dip Another taco trade or nah Slowly buying more $ALT $AMD and $CAKE. Will leave dry powder for any potential continued weakness going forward"
X Link @PGainz96934 2025-10-10T19:32Z XXX followers, XXX engagements

"$ALT Absolutely spot on; this captures what so many overlook in the MASH conversation. The market has understandably focused on biopsy data and M&A headlines but the prescribers perspective what hepatologists actually want to use day to day is where the real winners will emerge. Thats exactly why pemvidutide stands out. It checks nearly every box this survey identified: ✅ Robust pharmacologic weight loss with best-in-class muscle preservation comparable to leading GLP-1s demonstrating balanced and sustainable metabolic improvement ✅ Direct liver benefits in steatosis inflammation and fibrosis"
X Link @PGainz96934 2025-10-06T19:56Z XXX followers, 1804 engagements

"YES Altimmune $ALT absolutely has a strong case for Breakthrough Therapy Designation (BTD) once full 48-week data is in. For context: Survodutide (Boehringer) already got BTD for MASH with data that was inferior to ALTs. Survodutide showed 4762% MASH improvement and 6367% of patients achieving XX% liver fat reduction while Pemvidutide hit XX% MASH resolution (a higher bar) XX% achieving XX% fat reduction and XX% normalization of liver fat all with excellent tolerability and lean mass preservation. Compare that to Madrigals Rezdiffra which showed only 2630% NASH resolution and modest fat"
X Link @PGainz96934 2025-10-15T16:57Z XXX followers, XXX engagements

"--BREAKING NEWS-- As outlined by the President of AACE at Emory University (shown attached) this new meta-analysis reinforces what many have been missing about $ALT pemvidutide: MRI-based biomarkers cT1 and LFC are now recognized as the most reproducible and reliable ways to track real MASH treatment response outperforming all other methods. Whats striking is how Altimmunes data already exceed the thresholds considered clinically meaningful in this very analysis and across the MASLD/MASH field. 📊 Clinical Significance Benchmarks: A XX ms reduction in cT1 is widely accepted as a clinically"
X Link @PGainz96934 2025-10-13T18:17Z XXX followers, XXX engagements

"@HatedMoats Theyll have a difficult time competing until they purchase $ALT"
X Link @PGainz96934 2025-10-16T20:47Z XXX followers, XX engagements

"Lets address the latest round of falsehoods being pushed by the usual bashers and disinfo accounts around $ALT point by point. Its becoming obvious that certain accounts are operating with remarkably high posting volume and alleged coordination raising legitimate questions about whether theres an organized effort behind them. I cant speak to who funds or manages them but when one handle (in the screenshot below) posts anti- $ALT content many times per day 24/7 for many months it gives the appearance of inauthentic or coordinated activity. So far on this fine Sunday morning multiple anti -"
X Link @PGainz96934 2025-10-12T16:17Z XXX followers, XXX engagements